Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Cidara Therapeutics Inc (NASDAQ: CDTX) closed the day trading at $0.51 down -24.54% from the previous closing price of $0.68. In other words, the price has decreased by $-24.54 from its previous closing price. On the day, 3.7 million shares were traded. CDTX stock price reached its highest trading level at $0.648 during the session, while it also had its lowest trading level at $0.5002.
Ratios:
For a better understanding of CDTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.55 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.41.
On September 22, 2021, WBB Securities Upgraded its rating to Strong Buy which previously was Buy but kept the price unchanged to $6.25.
On March 04, 2021, Aegis Capital started tracking the stock assigning a Buy rating and target price of $9.Aegis Capital initiated its Buy rating on March 04, 2021, with a $9 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Tari Leslie sold 21,029 shares for $0.67 per share. The transaction valued at 14,085 led to the insider holds 258,681 shares of the business.
Sandison Taylor sold 20,662 shares of CDTX for $13,839 on Mar 11 ’24. The Chief Medical Officer now owns 347,095 shares after completing the transaction at $0.67 per share. On Mar 11 ’24, another insider, Ward Shane, who serves as the COO & CLO of the company, sold 20,473 shares for $0.67 each. As a result, the insider received 13,713 and left with 198,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDTX now has a Market Capitalization of 46569104 and an Enterprise Value of 17272402. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.82 while its Price-to-Book (P/B) ratio in mrq is 5.78. Its current Enterprise Value per Revenue stands at 0.305 whereas that against EBITDA is -0.547.
Stock Price History:
The Beta on a monthly basis for CDTX is 1.09, which has changed by -0.36355138 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, CDTX has reached a high of $1.48, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is -33.45%, while the 200-Day Moving Average is calculated to be -38.65%.
Shares Statistics:
Over the past 3-months, CDTX traded about 697.34K shares per day on average, while over the past 10 days, CDTX traded about 771070 shares per day. A total of 90.62M shares are outstanding, with a floating share count of 81.59M. Insiders hold about 9.96% of the company’s shares, while institutions hold 29.71% stake in the company. Shares short for CDTX as of 1711584000 were 195381 with a Short Ratio of 0.28, compared to 1709164800 on 221355. Therefore, it implies a Short% of Shares Outstanding of 195381 and a Short% of Float of 0.22.
Earnings Estimates
At present, Perspective Therapeutics, Inc. analysts are actively evaluating the performance of Cidara Therapeutics Inc (CDTX) in the stock market.The consensus estimate for the next quarter is $0.51, with high estimates of $2.22 and low estimates of $25.80.
